A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement. (CONTINUUM LINT)

January 5, 2026 updated by: Queen Mary University of London

A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection (as Measured by Change in Current) to Standard Measurements of Change in Venous and Arterial Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.

The main goal of this study is to see if a wearable device can reliably track changes in lactate levels in the body. We'll compare the device's readings to standard blood tests to ensure accuracy. If successful, this device could reduce the need for frequent blood tests during surgery recovery, making patients more comfortable. It might also be useful in emergency rooms for quick diagnoses, especially for patients with chest pain.

This study will take place at Barts Hospital with patients having planned coronary artery bypass graft (CABG) and/or replacement valve surgery. Participants will wear the sensors on their upper arm, during which the sensors will continuously measure lactate levels. Participants will also have hourly blood samples taken.

In the future, the data from this new device will be used to train computer algorithms to provide quick responses that help manage a patient's condition, improving future medical care and technology.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Summary of the study design and methodology

The research nurse or doctor will meet with the patient to explain the study and check the following:

Pre-screening: The research nurse, who may also be part of the patient's direct care team, will look at the records for patients who are attending St Bartholomew's hospital for cardiac surgery for grafts and/or valve replacement.

Informed Consent: If the patient is eligible, and would like to take part in the study, the research nurse or doctor will ask the patient to sign a consent form indicating their willingness to participate in the study.

Screening: The research nurse or doctor will collect demographic information from the patient and ensure the patient meets the study's inclusion and exclusion criteria.

Sensor Application: Up to 5 days pre-surgery, the research nurse will place two lactate sensors on the patient's arm. The sensor has a 24 hour warm-up period prior to continuously measuring the patient's lactate levels.

Pre-Surgery Admission: The research nurse will gather details about the patient's medical history and current medications. The patient will have their blood pressure, heart rate, respiratory rate, weight, and height measured, and an ECG performed. Baseline blood samples will be collected as per the standard of care pre-CABG and/or valve surgery.

CABG and/or replacement valve surgery: The patient will then undergo their planned CABG and/or replacement valve surgery as usual.

Blood Sampling: The patient will have hourly blood samples taken through the tubes inserted for their surgery for up to 14 hours to compare with the sensor readings. These samples will include 12 arterial lactate, 12 central venous lactate, and 12 venous troponin samples. Hourly measurements of the patient's blood pressure, heart rate, and respiratory rate will be taken, and any medication changes will be noted.

Sensor Removal: Up to 48 hours post-surgery, the sensors will be removed, and the patient's skin will be checked for any changes, like a rash. The patient will also have their blood pressure, heart rate, and respiratory rate measured, and an ECG performed. Any changes to the patient's medication will be noted.

Follow-Up: The study team will monitor the patient for up to 24 hours after the sensor is removed or until the patient is discharged from the hospital (whichever is earlier). The study team will note any medication changes, measure the patient's blood pressure, heart rate, and respiratory rate, and perform an ECG.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Able and willing to give informed consent
  • ≥18 to ≤ 90 years old

  • Successful surgery as defined by the below criteria (which will be recorded in the eCRF):

    • Operative Success: The successful completion of coronary artery bypass grafting (CABG) and/or valve insertion with grafts and/or valves
    • Absence of the following complications:
    • Significant bleeding requiring reoperation
    • Evidence of major life-changing stroke

Exclusion Criteria:

  • Previous coronary artery bypass grafting
  • Recent acute coronary syndrome (within 4 weeks of planned consent date)
  • Heart failure with EF less than 35% (from TTE or CT from past 6 months - if both available lower value will be used).
  • Chronic severe renal failure (estimated eGFR less than 30 mL/min/1.73m2 by the MDRD formula recorded at time of consent)
  • Severe anaemia (Hb less than 10 recorded at time of consent)
  • Known or suspected allergies to medical grade silicone adhesives
  • Pre-existing skin condition on the upper arm where the device would be applied, including recent burns/ scalds, open wounds or clinically significant skin lesions.
  • Patients with implanted medical devices such as pacemakers or other CLMs
  • Severe liver cirrhosis (≥ stage III)
  • Lymphoedema or pitting oedema at the time of consent
  • Pregnancy
  • History of ongoing malignant disease
  • Hypoalbuminaemia (less than 35 g/L recorded at time of consent)
  • Those lacking capacity to consent or are deemed vulnerable adults
  • Unable to speak English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Investigational Lactate Device
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device
Device: Continuous Lactate Monitoring Device
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Continuous lactate sensor measurement compared venous and arterial blood gas lactate measurements.
Time Frame: 14 hours
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and laboratory lactate measurements. Evaluate the change in interstitial fluid lactate measurements via a surrogate output of change in current (nA; using an investigational device by Abbott Diabetes Care Ltd.) to local Radiometer ABL 90 venous and arterial blood gas lactate measurements measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
14 hours
Continuous lactate sensor measurement compared Troponin-T
Time Frame: 14 hours
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and venous laboratory measurements of high-sensitivity troponin-T. Evaluate the relationship between the current (nA) output of a continuous interstitial fluid lactate monitor (using an investigational device by Abbott Diabetes Care Ltd.) and venous laboratory measurements of high-sensitivity troponin-T measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
14 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relationship between arterial and venous lactate measurements
Time Frame: 14 hours
Correlation coefficients describing the strength of association between arterial and central venous lactate measurements measured hourly up to 12 samples within a 14- hour period post-elective CABG and/or valve replacement surgery.
14 hours
Relationship between arterial and venous lactate and venous troponin measurements
Time Frame: 14 hours
Correlation coefficients describing the strength of association between arterial and central venous lactate and venous troponin measured hourly up to 12 samples within a 14-hour period post-elective CABG and/or valve replacement surgery.
14 hours
Functionality of the device for up to 48 hours post-surgery.
Time Frame: 48 hours
Proportion of devices that are able to give a continuous electrical signal for the duration of use post-surgery.
48 hours
Evaluate safety of lactate sensor
Time Frame: Up to 8 days
Number of patients experiencing adverse reactions or serious adverse reactions to the lactate investigational device.
Up to 8 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen Mary University of London

Investigators

  • Study Chair: Prof Anthony Mathur, Queen Mary University of London

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2025

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

September 16, 2024

First Submitted That Met QC Criteria

September 16, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 346076

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Bypass

Clinical Trials on Continuous Lactate Monitoring Device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe